Feb 01, 2023 / NTS GMT
Unidentified Participant
Welcome to the C-Suite Series presented by ChannelChek and Noble Capital Markets. Noble's an SEC-registered, FINRA-licensed broker dealer and the source of the equity research available on ChannelChek. Today's interview features Cocrystal Pharma, Nasdaq ticker symbol COCP. Noble Senior Research Analyst, Robert LeBoyer, interviews Cocrystal Pharma's CFO and Co-CEO, James Martin.
Visit channelchek.com or click the link in the description to access equity research, news, and advanced market data on Cocrystal Pharma, all at no cost. And now here's Robert and James.
Robert LeBoyer - Noble Capital Markets - Analyst
Hello. I'm Robert LeBoyer, Senior Biotechnology Analyst at Noble Capital. With me today is Jim Martin, CFO and Co-CEO of Cocrystal Pharma. The company is developing drugs for infectious diseases such as coronavirus, influenza virus, norovirus, and several others. Its unique technology is based on structure-based drug discovery and was originally developed by Roger Kornberg, a Nobel-Prize-winning scientist and founder of the company.
Cocrystal Pharma Inc at Noble Capital Markets and Channelcheck C-Suite Interview Series (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot